[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-injury":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,76,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100620637","muscle-damage-of-the-tfl-tensor-fascia-latae-during-total-hip-arthroplasty-tha-through-direct-anterior-approach-daa-100620637",false,"NCT07360210","Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA)","Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA), Evaluation of the Correlation With Short Term Functional Results","TFL","Inclusion Criteria:\n\n* adult (\\>18 years old),\n* patient undergoing primary Total Hip Arthroplasty through Direct Anterior Approach for osteoarthritis\n\nExclusion Criteria:\n\n* hip dysplasia\n* leg length discrepancy greater than 2cm\n* history of homolateral hip surgery\n* neuromuscular pathology\n* patients declining the protocol","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Direct Anterior Approach (DAA) is known to cause damage to the TFL during the surgical approach, the point of this study is to evaluate the impact between the severity of the per operative TFL damage and the functional short term results.",[27,28,29,30,31,32,33],"Hip Joint","Surgery","Arthroplasty","Replacement","Surgical Wound","Muscle Injury","Fascia Lata",[35,36],"TFL damage","Total Hip Arthroplasty through Direct Anterior Approach","NOT_YET_RECRUITING","2026-01-14",{"date":40,"type":41},"2026-01-22","ACTUAL",{"date":43,"type":21},"2026-02",{"date":45,"type":21},"2026-10",{"name":47,"class":48},"University Hospital, Bordeaux","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100496624","improving-tissue-repair-after-injury-in-the-muscle-tendon-interface-muscle-tissue-injury-100496624","NCT05746650","Improving Tissue Repair After Injury in the Muscle-tendon Interface Muscle Tissue Injury","Regulation of Protein Turnover in Connective Tissue From Muscle and Tendon Following Muscle Tissue Injury","GH-MTJ","Inclusion Criteria:\n\n* Healthy men and women scheduled to undergo reconstructive knee surgery\n* BMI 18-35\n\nExclusion Criteria:\n\n* Former or current use of growth hormone or anabolic steroids\n* Use of corticosteroids in the past 3 months\n* Use of any medication known to affect muscle or tendon turnover\n* Former participation in a study using deuterated water\n* Chronic diseases",true,"35 Years",{"count":61,"type":21},40,[24],"The study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of GH or placebo following or without neuromuscular electrical stimulation of hamstring muscles.The overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.",[32],"RECRUITING","2025-09-19",{"date":68,"type":41},"2025-09-24",{"date":70,"type":41},"2023-02-24",{"date":72,"type":21},"2027-09-01",{"name":74,"class":48},"Bispebjerg Hospital",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":75},"100455907","the-role-of-surgical-approach-on-residual-limping-after-total-hip-arthroplasty-100455907","NCT05216666","The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty","Abductor Insufficiency After Total Hip Arthroplasty; Risk Factors and Diagnosis","HSS","Inclusion Criteria:\n\n* Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty.\n* Ability to understand and write swedish.\n\nExclusion Criteria:\n\n* Impaired funktion of the contralateral hip or knees causing limping.\n* Neuromuscular diseases\n* Postoperative leg length discrepancy excceding 1 cm\n* Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.","40 Years","80 Years",{"count":87,"type":21},580,[24],"Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.",[91,92,93,32,94],"Hip Osteoarthritis","Muscle Weakness","Muscle Atrophy","Arthroplasty Complications",[96,97,98,99,100],"abductor","approach","limp","Trendelenburg","gluteus medius","2025-04-05",{"date":103,"type":41},"2025-04-09",{"date":105,"type":41},"2022-05-11",{"date":107,"type":21},"2028-12",{"name":109,"class":48},"Sahlgrenska University Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":58,"sex":118,"minAge":84,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":75},"100460712","biological-variables-associated-with-the-response-to-intensive-training-in-athletes-100460712","NCT05279196","Biological Variables Associated With the Response to Intensive Training in Athletes","Biological Variables Associated With the Response to Intensive Training in Athletes (CareStress)","CareStress","Inclusion Criteria:\n\n* Senior male athlete aged between 40 and 60 inclusive\n* Athlete following a program over a season of muscle building at CREPS, the objective of which is to improve their performance in a middle-distance race.\n\nExclusion Criteria:\n\n* Subject having a contraindication to follow the complete muscle building program at CREPS with in particular a contraindication to the measurement of muscle mass by Magnetic Resonance Imaging\n* Subject presenting all criteria which can by themselves alter the function of the respiratory muscles such as chronic obstructive pulmonary disease, heart failure, systemic infection, neuromuscular pathology, psychiatric pathology, metabolic disorder.\n* Subjects with coagulopathy or thrombocytopenia.\n* Use of anabolic drugs to increase muscle mass\n* Subject suspected of doping\n* Subject allergic to xylocaine","MALE","60 Years",{"count":61,"type":21},[24],"There is in humans, at the muscular level, a great interindividual variability in response to the same mechanical stress. This phenotypic variability is multifactorial, influenced by environmental factors as well as multiple genetic variants. Thus, for the same level of muscle damage, two subjects with the same anthropometric characteristic, the same age, with the same medical history and the same level of physical activity, will present a variable level of muscle regeneration underpinned by the biological function of muscular stem cells and their microenvironment. Thus, faced with the same training, some athletes will develop iterative muscular lesions and more disabling repair deficits than others without knowing the reason of this greater susceptibility.\n\nIndeed, the links between the genotype of the skeletal muscle fiber and its response to exercise, as well as the regulation of muscle mass are poorly understood. Yet, in young adults, up to 70% of the observed variability in muscle strength and size is hereditary. This heritability of muscle size and strength seems to be lower in older people, probably related to increased comorbidity. Numerous experiments with athletes subjected to the same resistance exercise training have identified good and bad hypertrophic skeletal muscle responders. However, genetic variants that contribute to skeletal muscle strength and mass are largely understudied while a growing body of evidence indicates that epigenetic effectors, which modulate gene expression, may contribute to human muscle response heterogeneity to the same mechanical stress. Thus, to date, no analysis of the role of the interaction between genetic and epigenetic factors involved in the muscle functional response to exercise exists. The main hypothesis is that the epigenetic status of muscle stem cells (satellite cells) is an important contributor in muscle mass response to exercise by modulating chromatin architecture.\n\nThus this study will identify the epigenetic modifications induced by training and their interaction with the genetic factors involved in the response of the biological function of the satellite cells to this training and on the other hand, to be able to link it to a blood signature.",[32],"2024-09-09",{"date":126,"type":41},"2024-09-19",{"date":128,"type":21},"2025-09",{"date":130,"type":21},"2029-03",{"name":132,"class":48},"University Hospital, Montpellier"]